本帖最后由 橙色雨丝 于 2015-4-27 20:10 编辑
这是来自加拿大的一份临床研究报告,内容主要是关于用放疗治疗局限性的MALT淋巴瘤。文章发表在2003年美国临床肿瘤期刊上,虽然时间过去非常久了,但是考虑到在过去的十几年中局限期的MALT治疗方面并没有太大突破,所以把摘要翻译如下并附上原文,供论坛上新近被诊断为MALT的彩虹们参考。
Localized Mucosa-AssociatedLymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent ClinicalOutcome 局限性的MALT淋巴瘤用放疗获得极好的临床结果
Purpose: 目的 Extranodal marginal zoneB-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is a distinctlymphoma with unique clinicopathologic features. We report the clinical outcomeof stage I and II MALT lymphoma treated with involved field radiation therapy(RT). MALT淋巴瘤是结外边缘区淋巴瘤的一个分型,具有独特的临床病理特点。我们在这里报告用受累野放疗治疗I-II期MALT淋巴瘤的临床结果。
Patients and Methods: 患者及方法 From 1989 to 2000, 103patients with stage IE and IIE disease were referred. Their median age was 60years, with a 2:1 female predominance. Presenting sites were stomach (17patients), orbital adnexa (31 patients), salivary glands (24 patients), thyroidgland (13 patients), and other sites (18 patients). Ninety-three patientsreceived RT— 85 received RT alone, and eight received chemotherapy and RT—witha median dose of 30 Gy. The median follow-up time was 5.1 years. 从1989年到2000年,共收治了103例IE期和IIE期的患者。他们的中位年龄为60岁,女性对男性的比例为2:1。病灶包括胃(17例),眼眶(31例),唾液腺(24例),甲状腺(13例),及其它部位(18例)。93例患者接受放疗,其中85例仅接受了放疗,8例接受了化疗和放疗-中位剂量为30格瑞。中位随访时间为5.1年。
Results:结果 A complete response (CR) toRT alone was achieved in 84 of 85 patients. Among CR patients, 14 experiencedrelapse. Relapse sites were mostly contralateral paired-organ or distant MALTlocations and, infrequently, lymph nodes. The crude local control rate with RTwas 95.3% (81 of 85 patients). No relapses were observed in patients withstomach or thyroid lymphoma, whereas 14 of 63 patients (22%) experiencedrelapse in the other sites. The overall 5-year survival rate was 98%, and thedisease-free survival rate was 77%. Transformed lymphoma was observed in 14% ofpatients (two of 14) experiencing relapse. 85例患者中有84例通过单独放疗获得了完全缓解。在完全缓解的患者中,有14例出现了复发。复发的部位主要是对侧器官或远端MALT部位,淋巴结侵犯少见。放疗的局部控制率为95.3%(85例中的81例)。胃和甲状腺MALT未观察到复发,63例患者中复发的14例(22%)出现在其它部位。5-年的总生存率为98%,无疾病生存率为77%。在14例复发患者中观察到2例转化淋巴瘤(14%)。
Conclusion: 结论 Moderate-dose RT achievedexcellent local control in localized MALT lymphomas and had curative potentialfor three fourths of the patients. Gastric and thyroid MALT lymphomas hadbetter outcome, whereas distant failures were common for other sites. Despiterelapse, the disease often maintained an indolent course. 局限性的MALT淋巴瘤通过温和剂量的放疗可以达到极好的局部控制,大约3/4的患者可能被治愈。消化道和甲状腺的MALT淋巴瘤的预后更好,而其它部位的MALT可以出现远端的复发。即使复发后,这种疾病通常还保持惰性的临床特征。
|